EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÁ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÁV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ

Trial Profile

EVEROLIMUS VERSUS MYCOPHENOLIC ACID IN SIMULTANEOUS PANCREAS AND KIDNEY TRANSPLANTATION TO EVALUATE THE DIFFERENCES IN RETINAL NEOVASCULARIZATION IN PATIENTS WITH DIABETIC RETINOPATHY EVEROLIMUS VERSUS MYKOFENOLOVÁ KYSELINA U PACIENTŮ PO KOMBINOVANÁ TRANSPLANTACI LEDVINY A SLINIVKY BŘIŠNÍ ZA ÚČELEM ZHODNOCENÍ VÝVOJE NOVOTVORBY CÁV NA SÍTNICI U PACIENTŮ S DIABETICKOU RETINOPATIÍ

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2016

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate mofetil (Primary)
  • Indications Kidney-pancreas transplant rejection
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top